[{"orgOrder":0,"company":"Argenx","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Halozyme Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0.75,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.75,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ J.P. Morgan"},{"orgOrder":0,"company":"Argenx","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Medison Pharma"},{"orgOrder":0,"company":"Argenx","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Zai Lab","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Zai Lab"},{"orgOrder":0,"company":"Argenx","sponsor":"Fujifilm Diosynth Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Soleo Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Argenx","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Zai Lab","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Zai Lab"},{"orgOrder":0,"company":"Argenx","sponsor":"Bluebird Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Bluebird Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Elektrofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alfa","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Argenx \/ Argenx","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Empasiprubart","moa":"C2","graph1":"Immunology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"FairJourney Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"PORTUGAL","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Argenx \/ Argenx","highestDevelopmentStatusID":"3","companyTruncated":"Argenx \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Argenx \/ Argenx","highestDevelopmentStatusID":"1","companyTruncated":"Argenx \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0.37,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.37,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":1.27,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.75,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ J.P. Morgan"},{"orgOrder":0,"company":"Argenx","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":1.27,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.75,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ J.P. Morgan"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Rambam Health Care Campus","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argenx \/ Argenx","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase IV","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Zai Lab"},{"orgOrder":0,"company":"Argenx","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ IQVIA"},{"orgOrder":0,"company":"Argenx","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ IQVIA"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod PH20","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Hansa Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod","moa":"||Antibodies","graph1":"Immunology","graph2":"Preclinical","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argenx \/ Argenx","highestDevelopmentStatusID":"4","companyTruncated":"Argenx \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argenx \/ Argenx","highestDevelopmentStatusID":"1","companyTruncated":"Argenx \/ Argenx"}]
Find Immunology Clinical Drug Pipeline Developments & Deals by Argenx
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
